Evidence map›Paper›PMID 32001707›Full record

ArticleNature communications2020

Dual functionalized brain-targeting nanoinhibitors restrain temozolomide-resistant glioma via attenuating EGFR and MET signaling pathways.

Xiangqi Meng, Yu Zhao, Bo Han, Caijun Zha, Yangong Zhang, Ziwei Li, Pengfei Wu, Tengfei Qi, Chuanlu Jiang, Yang Liu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 165 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Xiangqi Meng *Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Neuroscience Institute, Heilongjiang Academy of Medical Sciences, 150086, Harbin, China.
Yu Zhao *State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Functional Polymer Materials of Ministry of Education, College of Chemistry, Nankai University, 300071, Tianjin, China.
Bo HanDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Neuroscience Institute, Heilongjiang Academy of Medical Sciences, 150086, Harbin, China.
Caijun ZhaDepartment of Laboratory Diagnosis, The Second Affiliated Hospital of Harbin Medical University, 150086, Harbin, China.
Yangong ZhangDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Neuroscience Institute, Heilongjiang Academy of Medical Sciences, 150086, Harbin, China.
Ziwei LiDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Neuroscience Institute, Heilongjiang Academy of Medical Sciences, 150086, Harbin, China.
Pengfei WuDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Neuroscience Institute, Heilongjiang Academy of Medical Sciences, 150086, Harbin, China.
Tengfei QiDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Neuroscience Institute, Heilongjiang Academy of Medical Sciences, 150086, Harbin, China.
Chuanlu JiangDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Neuroscience Institute, Heilongjiang Academy of Medical Sciences, 150086, Harbin, China. jcl6688@163.com.
Yang LiuState Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Functional Polymer Materials of Ministry of Education, College of Chemistry, Nankai University, 300071, Tianjin, China. yliu@nankai.edu.cn.
Jinquan CaiDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Neuroscience Institute, Heilongjiang Academy of Medical Sciences, 150086, Harbin, China. caijinquan@hrbmu.edu.cn.
Harbin Medical University · CNSecond Affiliated Hospital of Harbin Medical University · CNNankai University · CNState Key Laboratory of Medicinal Chemical Biology

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activation of receptor tyrosine kinase (RTK) protein is frequently observed in malignant progression of gliomas. In this study, the crosstalk activation of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) signaling pathways is demonstrated to contribute to temozolomide (TMZ) resistance, resulting in an unfavorable prognosis for patients with glioblastoma. To simultaneously mitigate EGFR and MET activation, a dual functionalized brain-targeting nanoinhibitor, BIP-MPC-NP, is developed by conjugating Inherbin3 and cMBP on the surface of NHS-PEG

Indexed as

Drug Resistance, NeoplasmSignal TransductionAnimalsBinding SitesBrainCell Line, TumorCell Membrane PermeabilityDNA DamageDNA RepairE2F1 Transcription FactorErbB ReceptorsGliomaMice, Inbred BALB CMice, NudeNanoparticlesPhosphorylationE2F1 protein, humanE2F1 Transcription FactorErbB ReceptorsProto-Oncogene Proteins c-metTemozolomide

Identifiers

PMID32001707
PMCPMC6992617
OpenAlexW3003662453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.